Last checked at 
Mercia Asset Management PLC - regionally-focused asset manager - Updates on assets in life sciences portfolio. Among updates, Mercia says gene editing firm Oxford Genetics Ltd posts third successive year of more than 100% revenue growth. Life sciences investments have value of GBP28.6 million, 33% of total portfolio as at March 31. "The life sciences sector represents a significant growth area in the UK's regions and is well positioned to benefit from current trends," Chief Executive Officer Mark Payton said.
Current stock price: 19.05 pence
Year-to-date change: down 29%
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
